宜宾双眼皮哪做的比较好宜宾开眼角加割双眼皮多少钱,宜宾双眼皮手术恢复自然,宜宾脂肪面部填充失败,宜宾哪祛斑好,宜宾怎样祛斑效果好,宜宾割双眼皮算整容吗,宜宾隆鼻后几天拆线

WASHINGTON, July 10 (Xinhua) -- U.S. space shuttle Atlantis docked with the International Space Station on Sunday morning after nearly two days of flight.Commander Christopher Ferguson guided space shuttle Atlantis to a docking with the station at 11:07 a.m. EDT (1507 GMT) when the two spacecrafts were flying 240 miles up over east of New Zealand, according to NASA.This was the 12th and final time Atlantis docked to the space station. It was the 46th shuttle docking to a space station, nine to the Russian Mir station and 37 to the International Space Station.The space shuttle Atlantis is seen with part of the structure of the International Space Station in the foreground and the earth in the background as it approaches the station for docking in this still image from NASA TV July 10, 2011. The shuttle and station crews will open hatches and hold the traditional welcome ceremony at about 1:19 p.m. EDT (1719 GMT). The combined crew of 10 will begin more than a week of docked operations, transferring vital supplies and equipment to sustain station operations once the shuttles are retired.Atlantis lifted off on Friday morning from Kennedy Space Center in Florida, on the 135th and final flight in NASA's shuttle program.It is the 33rd voyage for Atlantis. Its return to the earth later this month will mark the end of the 30-year shuttle program.

SAN FRANCISCO, June 8 (Xinhua) -- Facebook Inc. will be probed by European Union (EU) regulators over its latest facial recognition feature rolling out worldwide, U.S. media reported on Wednesday.The feature, called Tag Suggestions, uses face recognition software to match users' new photos to other photos they are tagged in. It groups similar photos together and suggests the name of the friend in the photos.Facebook rolled out the feature in the United States late last year, where users can opt out of the feature by going to their private settings. But Facebook switched it on by default without telling users first when it became available on Tuesday in countries outside of the United States.A group of privacy watchdogs from 27 EU nations will study the measure for possible rule violations, a Luxembourg official of Article 29 Data Protection Working Party told Bloomberg. The Working Party, an independent EU advisory body on data protection and privacy, comprises the data protection regulators of all the 27 EU member states."Tags of people on pictures should only happen based on people' s prior consent and it can't be activated by default," said the Luxembourg official, Gerald Lommel. He noted that such automatic features "can bear a lot of risks for users" and the European data- protection regulators will "clarify to Facebook that this can't happen like this."Authorities in Britain and Ireland said they are also looking into the new function on Facebook. The British Information Commissioner's Office told Bloomberg that "the privacy issues that this new software might raise are obvious," saying it is "speaking to Facebook" about the issue.Facebook has been under scrutiny by EU regulators for several privacy concerns, such as users' default settings and how the company uses the information collected from its social network website.

WELLINGTON, Sept. 27 (Xinhua) -- New Zealand and Japanese scientists are teaming up to develop healthier foods under two government-funded "functional foods" projects.One project, to be led by New Zealand's Massey University, will work with New Zealand food companies to create and develop a functional food with specific health enhancing effects for menopausal women, New Zealand Science and Innovation Minister Wayne Mapp announced Tuesday.The other project, to be led in New Zealand by Plant and Food Research, would use mass spectrometry to develop a "metabolic atlas" of the chemical composition of allium vegetables, such as onions and garlic, which the horticultural industry could use to develop new food products with health benefits.Mapp said the two research projects would be awarded a total of 1 million NZ dollars (782,000 U.S. dollars) in funding to strengthen collaborative research relationships between New Zealand and Japan, Mapp said."These research projects have strong commercial potential, including through the Japanese market, and so have the potential to benefit our economy," said Mapp."The government is committed to building and strengthening research relationships with other countries that will achieve world-class scientific results and lead to new innovative technologies."The two projects awarded funding under Ministry of Science and Innovation's Japan Science and Technology Agency (JST) funding round focus on functional foods. The ministry and Japan each fund half the cost of each research project awarded funding.

WASHINGTON, July 5 (Xinhua) -- Intake of high levels of folate, a water-soluble B vitamin that occurs naturally in food, may reduce colorectal cancer risk, according to a new study published Tuesday in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. "We found that all forms and sources of folate were associated with lower risk of colorectal cancer," said lead author Victoria Stevens, of the American Cancer Society. "The strongest association was with total folate, which suggests that total folate intake is the best measure to define exposure to this nutrient because it encompasses all forms and sources."Total folate includes naturally occurring food folate and folic acid from fortified foods and dietary supplements.The research team investigated the association between folate intake and colorectal cancer among 99,523 participants in the Cancer Prevention Study II Nutrition Cohort; a total of 1,023 participants were diagnosed with colorectal cancer between 1999 and 2007, a period entirely after folate fortification began. Neither higher nor lower risk was observed during the first two years of follow-up (1999 to 2001), while associations were statistically significantly inverse for the subsequent years (2002 to 2007). The findings of this study add to the epidemiologic evidence that high folate intake reduces colorectal cancer incidence.Folates are essential nutrients needed to make components used for functions required for normal cell growth, including DNA synthesis and repair. Because these processes are critical for cell growth and differentiation, the relationship between folate intake and cancer development has been investigated in several cancers, and most extensively in colorectal cancer.

WELLINGTON, June 7 (Xinhua) -- Scientists in New Zealand have developed a new drug to fight previously untreatable hypoxic cancer tumors, which form in areas of the body starved of oxygen.The researchers at the Auckland University have entered an agreement for the clinical development of CEN-209, which was developed over 10 years of research, said a statement from the university Tuesday.CEN-209 was designed to enhance the effectiveness of radiotherapy and chemotherapy in solid hypoxic tumors, which were resistant to standard cancer therapies, said the statement. In lung cancer patients for example, about half of tumors had hypoxic regions.The new drug worked by damaging the DNA of hypoxic cancer cells, while leaving normal, healthy tissues alone.CEN-209 was designed and created by researchers at the university's Auckland Cancer Society Research Centre (ACSRC), using computer models of drug transport within tumors to accurately predict the anti-tumor activity of the drugs."Our computer models of drug transport developed in-house allowed the synthetic chemists to test their design theories and considerably shortened the discovery process," said Associate Professor Michael Hay, who led the ACSRC research chemists."CEN-209 improves markedly on previous agents in this class in terms of its ability to penetrate tumors, and this is reflected by its improved activity in the laboratory, when combined with long or short courses of radiotherapy," said researcher Professor Bill Wilson.Under the agreement between the university's Auckland UniServices Ltd. and California-based Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc., Centella will have exclusive rights to CEN-209, which it will develop and trial with Cancer Research UK.The work on CEN-209 is the culmination of a program initiated with funding from the U.S. National Cancer Institute, and more recently from the Maurice Wilkins Centre for Biodiscovery. Ongoing preclinical research on CEN-209 and a backup compound was funded by grants from the Auckland Medical Research Foundation, Genesis Oncology Trust and Health Research Council of New Zealand, said the statement.